Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

Wachovia Cuts EPS Estimates on ICN Pharma


Wachovia Securities cuts its estimates on ICN Pharmaceuticals (ICN) after the company said it sees Q3 EPS from operations of $0.08 to $0.13.

Analyst Michael Tong says he is surprised by the magnitude that the generic drug maker has lowered guidance. He believes the company's other operations (excluding North American) will probably experience weaknesses soon. The sheer magnitude of the shortfall suggests more problems than just royalty problems. Tong says if there is a pickup in Q4 royalty revenues it will only be modest.

Tong cut his Q3 EPS estimate to $0.10, down from $0.32 and lowered 2001 EPS to $0.93, from $1.15. He sees 2002 EPS estimate of $1.71. The stock outperformance is unlikely until observable operating improvements emerge. He rates the stock a market perform.


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus